The efficacy of pentoxifylline in suppressing the regulatory T (Tregs) cells in multiple myeloma (MM) patients undergoing autologous hematopoietic stem cell transplantation (ASCT) compared to the control group and its impact on disease outcome

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新: 2023年6月26日

适应症

试验速览

暂无简介。

•Patients with symptomatic MM
•Patients must be in complete response (CR) after primary therapy.
•MM patient must be a candidate for autologous hematopoietic stem cell transplantation (ASCT) as determined by treating physician.
•Age greater than or equal to 21 and less than or equal to 70 years old.
•HIV Negative and no active Hepatitis B or C.

•Patients with CNS Myeloma at time of enrollment.
•Patients with cardiac, pulmonary, hepatic diseases.
•Active autoimmune disease including but not limited to: Rheumatoid arthritis, Inflammatory bowel disease, Celiac disease, Systemic lupus erythematosis, Scleroderma or Multiple sclerosis.
•Use of systemic immunosuppressive medications, including tacrolimus, mycophenolate mofetil, sirolimus or cyclosporine A.
•Psychiatric illness which may make compliance to the clinical protocol unmanageable or which may compromise the ability of the patient to give informed consent.

发起方